Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$9.42 -0.3%	$7.60	$2.08 ▼ $9.72	$842.63M	-0.46	1.18 million shs	1.49 million shs
AVXL Anavex Life Sciences	$9.22 -2.4%	$10.52	$4.93 ▼ $14.44	$811.70M	0.8	917,968 shs	779,652 shs
IPHA Innate Pharma	$2.09 -0.5%	$1.98	$1.29 ▼ $3.51	$193.59M	0.22	7,604 shs	3,328 shs
TSHA Taysha Gene Therapies	$2.83 -4.7%	$2.65	$1.05 ▼ $3.31	$810.20M	0.98	2.80 million shs	1.85 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+3.17%	+17.68%	+18.27%	+92.86%	+343.66%
AVXL Anavex Life Sciences	-0.84%	-2.38%	-18.32%	+23.85%	+55.43%
IPHA Innate Pharma	+1.65%	-5.84%	-4.77%	-4.77%	-3.01%
TSHA Taysha Gene Therapies	+0.34%	+3.48%	+11.24%	+8.00%	+38.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.5599 of 5 stars	4.5	2.0	0.0	2.9	2.5	0.6
AVXL Anavex Life Sciences	3.7457 of 5 stars	3.5	1.0	4.7	2.1	0.8	0.6
IPHA Innate Pharma	2.441 of 5 stars	3.7	2.0	0.0	3.3	1.7	0.0
TSHA Taysha Gene Therapies	3.3487 of 5 stars	4.5	2.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$12.25	30.04% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	377.22% Upside
IPHA Innate Pharma	3.33	Buy	$11.00	426.32% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	192.78% Upside

Current Analyst Ratings Breakdown

Latest IPHA, AMLX, AVXL, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	AMLX Amylyx Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
8/27/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	9.61	N/A	N/A	$1.88 per share	5.01
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
IPHA Innate Pharma	$21.77M	8.85	N/A	N/A	$0.11 per share	19.00
TSHA Taysha Gene Therapies	$8.33M	92.68	N/A	N/A	$0.91 per share	3.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	0.00	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	0.00	N/A	N/A	-1,144.97%	-78.44%	-44.82%	11/12/2025 (Estimated)

Latest IPHA, AMLX, AVXL, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
AVXL Anavex Life Sciences	N/A	8.93	8.93
IPHA Innate Pharma	2.52	2.60	2.60
TSHA Taysha Gene Therapies	0.17	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
AVXL Anavex Life Sciences	31.55%
IPHA Innate Pharma	0.16%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
AVXL Anavex Life Sciences	11.40%
IPHA Innate Pharma	31.89%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
TSHA Taysha Gene Therapies	180	272.80 million	262.48 million	Optionable

IPHA, AMLX, AVXL, and TSHA Headlines

Recent News About These Companies

Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9

August 25 at 12:26 AM | msn.com

Kovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHA

August 24, 2025 | marketbeat.com

Critical Analysis: Taysha Gene Therapies (NASDAQ:TSHA) and Targeted Medical Pharma (OTCMKTS:TRGM)

August 19, 2025 | americanbankingnews.com

FY2025 Earnings Forecast for TSHA Issued By Chardan Capital

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for TSHA Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Negative Forecast for TSHA Earnings

August 17, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst Upgrade

August 15, 2025 | marketbeat.com

Wells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00

August 15, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00

August 14, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

August 13, 2025 | msn.com

4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...

August 13, 2025 | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

August 13, 2025 | marketbeat.com

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

August 13, 2025 | finance.yahoo.com

XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 13, 2025 | marketbeat.com

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

August 13, 2025 | msn.com

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028

August 13, 2025 | msn.com

What's Next: Taysha Gene Therapies's Earnings Preview

August 13, 2025 | benzinga.com

Taysha Gene Therapies Advances Rett Syndrome Trials

August 12, 2025 | tipranks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Taysha Gene Therapies, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, AMLX, AVXL, and TSHA Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$9.42 -0.03 (-0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$9.48 +0.06 (+0.69%)

As of 05:20 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Anavex Life Sciences NASDAQ:AVXL

$9.22 -0.23 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.56 +0.34 (+3.74%)

As of 07:48 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Innate Pharma NASDAQ:IPHA

$2.08 -0.02 (-0.90%)

As of 04:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Taysha Gene Therapies NASDAQ:TSHA

$2.83 -0.14 (-4.71%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 0.00 (-0.18%)

As of 07:52 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time